Volume 36 · Number 1
JANUARY 2006
Methodological Issues in Designing a Randomized Controlled Trial for Psychotic Depression: The STOP-PD Study
By Barnett S. Meyers, MD; Catherine Peasley-Miklus, PhD; Alastair J. Flint, MD, FRCPC, FRANZCP; Benoit H. Mulsant, MD; Anthony J. Rothschild, MD
The safety and efficacy of electroconvulsive therapy (ECT) has been documented for more than half a century, including among patients with major depressive disorder with psychotic features (MD-Psy) who have failed intensive antidepressant treatment. More recent studies from academic centers that use contemporary ECT standards have demonstrated response and remission rates exceeding 90% among patients with MD-Psy.
ABOUT THE AUTHORS
Dr. Meyers is professor of psychiatry, Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester, NY. Dr. Peasley-Miklus is research associate, Department of Psychiatry, Weill Medical College of Cornell University. Dr. Flint is professor, Department of Psychiatry, University of Toronto, and head, Geriatric Psychiatry Program, University Health Network, Toronto, Ontario, Canada; the Geriatric Program and Research Institute, Toronto Rehabilitation Institute, Toronto; and the Toronto General Research Institute, Toronto. Dr. Mulsant is professor of psychiatry, Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA; clinical director, Geriatric Mental Health Program, Centre for Addiction and Mental Health, Toronto, and professor, Department of Psychiatry, University of Toronto. Dr. Rothschild is Irving S. and Betty Brudnick Professor of Psychiatry, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA.
Address reprint requests to: Barnett S. Meyers, MD, New York Presbyterian Hospital Westchester, 21 Bloomingdale Road, White Plains, NY 10605; e-mail: bmeyers@med.cornell.edu.
Dr. Meyers disclosed no relevant financial relationships. Dr. Peasley-Miklus disclosed relevant financial relationships with Pfizer and Eli Lilly. Dr. Flint disclosed a relevant financial relationship with Pfizer Canada. Dr. Mulsant disclosed relevant financial relationships with Pfizer, Eli Lilly, Forest/Lundbeck, AstraZeneca, Janssen, and Alkermes. Dr. Rothschild disclosed relevant financial relationships with Lilly and Pfizer.
This article was supported in part by United States Public Health Service grants MH 62446, MH 62518, MH 62565, and MH 62624 from the National Institute of Mental Health.
What Do We Know and What Don’t We Know?
Jan Fawcett, MD
Psychotic Depression
Barnett S. Meyers, MD
A 38-year-old Man With Anxiety, Intrusive Violent Thoughts
Pharmacotherapy of Major Depression with Psychotic Features: What is the Evidence?
Carmen Andreescu, MD;
Benoit H. Mulsant, MD;
Anthony J. Rothschild, MD;
Alastair J. Flint, MD, FRCPC, FRANZCP;
Barnett S. Meyers, MD;
Ellen Whyte, MD
Challenges in Differentiating and Diagnosing Psychotic Depression
Anthony J. Rothschild, MD;
Benoit H. Mulsant, MD;
Barnett S. Meyers, MD;
Alastair J. Flint, MD, FRCPC, FRANZCP
Research Assessment of Patients With Psychotic Depression: The STOP-PD Approach
Alastair J. Flint, MD, FRCPC, FRANZCP;
Ayal Schaffer, MD, FRCPC;
Barnett S. Meyers, MD;
Anthony J. Rothschild, MD;
Benoit H. Mulsant, MD
The Clinical Significance of Psychotic Depression
Diana Feldman, MD
